Related Experiment Video
Updated: Jun 9, 2026

Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting
Published on: June 6, 2020
The economics of priority review vouchers
1Faculty of Economics, University of Siena, 53100, Italy. dimitri@unisi.it
Abstract:
Priority review vouchers (PRVs) were introduced in 2007 by the US Congress as an incentive mechanism to spur pharmaceutical firms' R&D efforts for neglected diseases (NDs). A voucher, which a firm can obtain upon approval of a new treatment for NDs, entitles the holder to prioritize the FDA review for any drug. The proposal generated much controversy regarding its ability to effectively stimulate R&D for NDs. Here, after reviewing the main issues of the debate, i use a stylized economic model to discuss the strength of PRVs as an economic incentive to invest in research. My findings suggest that R&D investments might be higher when the developer could prioritize a valuable compound.
More Related Videos
Related Concept Videos
Bioequivalence studies: Biowaivers
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Bioequivalence: Overview
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...

